Does Centene Corporation Cover Eliquis?

How Centene Corporation Structures Its Drug Coverage

Centene Corporation is one of the largest managed care organizations in the United States, serving over 28 million members across all 50 states. The company does not sell health insurance under a single brand. Instead, it operates through subsidiary brands tailored to specific market segments. Understanding which subsidiary manages your plan is the first step to confirming Eliquis coverage.

Key Centene Subsidiaries

Ambetter handles individual and family marketplace plans sold through the Affordable Care Act exchanges. WellCare operates Medicare Advantage, Medicare Part D, and some Medicaid plans. Centene also holds Medicaid managed care contracts in dozens of states under names like Peach State Health Plan (Georgia), Sunshine Health (Florida), Magnolia Health (Mississippi), and others. Each subsidiary maintains its own formulary, though Centene's central pharmacy benefit management team sets broad coverage guidelines that flow across brands.

Why Formularies Differ by Plan

A member enrolled in an Ambetter Silver plan in Texas may see Eliquis on a different tier than a WellCare Medicare Advantage member in Ohio. State regulations, federal Medicare rules, and negotiated rebates from Bristol-Myers Squibb and Pfizer all shape where Eliquis lands on each formulary. The Centers for Medicare & Medicaid Services (CMS) requires Medicare Part D plans to cover all anticoagulants as part of the "all or substantially all" protected class policy for certain drug categories, though direct oral anticoagulants (DOACs) like Eliquis do not fall under a formally protected class. CMS formulary standards still drive broad DOAC access on WellCare Part D plans [1].

Eliquis Formulary Placement Across Centene Plans

Eliquis (apixaban) is listed on most Centene subsidiary formularies, but the tier and cost-sharing structure vary. Across Ambetter marketplace plans, Eliquis typically appears on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). WellCare Medicare Part D plans most commonly place it on Tier 3.

Ambetter Marketplace Plans

On Ambetter formularies, Eliquis generally sits at the preferred brand level with a copay ranging from $40 to $90 per 30-day fill, depending on the metal tier of the plan. Bronze and Silver plans tend to have higher copays for brand-name drugs. Gold plans often cap brand copays at lower thresholds. Coinsurance models (where you pay a percentage rather than a flat dollar amount) are common on higher tiers, and a 25% to 33% coinsurance on a medication with a list price near $600/month can create significant out-of-pocket exposure before deductible is met.

WellCare Medicare Part D

WellCare Part D formularies typically list Eliquis on Tier 3. During the Initial Coverage Phase, copays for Tier 3 drugs often fall between $42 and $100, depending on the specific plan variant and region. Once a member enters the Coverage Gap (sometimes called the "donut hole"), manufacturer discounts under the Inflation Reduction Act provisions reduce brand-name drug costs. Starting in 2025, the $2,000 annual out-of-pocket cap on Medicare Part D spending applies, which substantially limits total Eliquis costs for Medicare beneficiaries over a calendar year [2].

Centene Medicaid Managed Care

Medicaid formulary rules are state-driven. In states where the Medicaid preferred drug list (PDL) includes Eliquis, Centene's Medicaid subsidiary will cover it with minimal cost-sharing ($0 to $3 copays in most states). Some state Medicaid programs prefer warfarin as the first-line anticoagulant due to its low cost and require prior authorization before covering a DOAC like Eliquis. The FDA prescribing information for apixaban supports its use for stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT), and pulmonary embolism (PE) [3].

Prior Authorization and Step Therapy Requirements

Most Centene subsidiary plans impose some form of utilization management on Eliquis. This typically means prior authorization, step therapy, or both.

What Prior Authorization Involves

Prior authorization (PA) requires your prescribing physician to submit clinical documentation to Centene's pharmacy benefit manager before the prescription is approved. The PA process confirms that the patient has an FDA-approved indication for apixaban, that dosing aligns with labeling (5 mg twice daily for most indications, or 2.5 mg twice daily for patients meeting at least two of three criteria: age ≥80, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL), and that no formulary-preferred alternative is more appropriate [3].

Step Therapy Protocols

Some Centene plans, particularly Medicaid managed care contracts, require a step through warfarin before Eliquis is approved. This means the patient must try warfarin first and either demonstrate a clinical failure (poor INR control, adverse reaction, or documented drug-food interaction burden) or meet an exception criterion (such as inability to attend regular INR monitoring). The American Heart Association and American College of Cardiology (AHA/ACC) 2019 focused update on atrial fibrillation management recommends DOACs over warfarin for most patients with nonvalvular AF who are eligible for oral anticoagulation, which can support step therapy override requests [4].

Turnaround Times

Standard PA decisions must be rendered within 72 hours for non-urgent requests and 24 hours for urgent/expedited requests under most state and federal regulations. If PA is denied, Centene plans provide an appeals process. Physicians can submit a peer-to-peer review request to discuss the clinical rationale directly with a Centene medical director.

Clinical Evidence Supporting Eliquis Coverage

Insurance coverage decisions are partly informed by clinical trial data and guideline recommendations. Eliquis has one of the strongest evidence bases among DOACs.

The ARISTOTLE Trial

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with atrial fibrillation and at least one additional stroke risk factor. At a median follow-up of 1.8 years, apixaban reduced stroke or systemic embolism by 21% compared to warfarin (HR 0.79, 95% CI 0.66-0.95, P=0.01). Major bleeding was 31% lower with apixaban (HR 0.69, 95% CI 0.60-0.80, P<0.001). All-cause mortality was also significantly lower (HR 0.89, 95% CI 0.80-0.99, P=0.047) [5].

The AMPLIFY Trial

For the treatment of acute venous thromboembolism, the AMPLIFY trial (N=5,395) demonstrated that apixaban was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE (RR 0.84, 95% CI 0.60-1.18) while causing significantly less major bleeding (RR 0.31, 95% CI 0.17-0.55, P<0.001) [6]. This dual advantage in efficacy and safety made apixaban a preferred choice across multiple guideline documents.

Guideline Endorsements

The 2023 ACC/AHA/ACCP/HRS guideline for diagnosis and management of atrial fibrillation gives DOACs a Class I recommendation (Level of Evidence A) over warfarin for stroke prevention in eligible AF patients [4]. The American Society of Hematology (ASH) 2020 VTE guidelines similarly recommend DOACs over vitamin K antagonists for VTE treatment in patients without cancer [7].

Dr. Craig January, lead author of the 2019 AHA/ACC AF guideline focused update, stated: "For patients with atrial fibrillation who require anticoagulation, DOACs are preferred over warfarin due to their favorable balance of efficacy, safety, and convenience" [4].

How to Reduce Your Eliquis Costs on a Centene Plan

Even with coverage, Eliquis copays can strain household budgets. Several strategies can lower what you actually pay.

Manufacturer Copay Assistance

Bristol-Myers Squibb and Pfizer offer the Eliquis Free Trial and Savings Card program for commercially insured patients. Eligible members can pay as little as $10 per month for up to 24 months. This card works with Ambetter and other Centene commercial plans. It does not work with Medicare, Medicaid, or other government-funded insurance programs per federal anti-kickback statute regulations.

State Pharmaceutical Assistance Programs

Several states offer pharmaceutical assistance programs (SPAPs) that supplement Medicare Part D or Medicaid coverage for high-cost medications. WellCare members in states with SPAPs may qualify for additional cost relief. Your state's Medicaid office or the Medicare.gov plan finder can identify available programs.

Formulary Exception Requests

If your Centene plan places Eliquis on a non-preferred tier (Tier 4) and you face high cost-sharing, your physician can submit a formulary exception request asking the plan to cover Eliquis at the preferred tier copay. Success depends on documenting medical necessity, such as prior adverse reactions to other DOACs (rivaroxaban, edoxaban) or warfarin, or clinical factors that make apixaban the safest option (e.g., renal dosing flexibility, twice-daily dosing preferred over once-daily for adherence monitoring).

The $2,000 Medicare Part D Cap

Since 2025, the Inflation Reduction Act caps total out-of-pocket Part D spending at $2,000 per year. WellCare Medicare Part D members who previously faced thousands in annual anticoagulant costs now have a hard ceiling. CMS also introduced the Medicare Prescription Payment Plan, allowing beneficiaries to spread their out-of-pocket costs across monthly installments throughout the year rather than paying large sums at the pharmacy counter early in the benefit year [2].

Apixaban Dosing and What Your Plan Will Approve

Centene plans follow FDA-labeled dosing when adjudicating claims. Understanding the approved dose ranges helps avoid claim rejections.

Standard Dosing

The standard dose for stroke prevention in nonvalvular AF is 5 mg orally twice daily. For acute DVT/PE treatment, the loading dose is 10 mg twice daily for 7 days, followed by 5 mg twice daily. For secondary prevention after initial treatment, the dose drops to 2.5 mg twice daily [3].

Dose Reduction Criteria

The reduced dose of 2.5 mg twice daily for AF applies when a patient meets at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater. Claims submitted for the reduced dose without documented clinical justification may trigger a pharmacist review. The ARISTOTLE trial subanalysis confirmed that the dose-reduction algorithm maintained apixaban's efficacy and safety advantages across subgroups [8].

Quantity Limits

Most Centene plans impose quantity limits of 60 tablets per 30-day supply (reflecting twice-daily dosing) or 180 tablets per 90-day mail-order fill. During the 7-day loading phase for VTE treatment, a higher quantity (up to 140 tablets for the initial fill covering load + maintenance) may require PA override.

Switching From Warfarin to Eliquis on a Centene Plan

Many patients covered by Centene plans are initially prescribed warfarin due to step therapy requirements or physician preference. Switching to Eliquis is clinically common and well-supported.

When Switching Makes Sense

The AHA/ACC guidelines support switching from warfarin to a DOAC when INR control is suboptimal (time in therapeutic range below 65-70%), when monitoring burden is excessive, or when drug-food or drug-drug interactions with warfarin create safety concerns [4]. A 2020 retrospective cohort study published in JAMA Network Open (N=50,787) found that patients switched from warfarin to apixaban had 37% fewer major bleeding events (HR 0.63, 95% CI 0.56-0.71) compared to those remaining on warfarin [9].

Dr. Renato Lopes, co-principal investigator of the ARISTOTLE trial, noted: "The consistent safety signal favoring apixaban over warfarin persists across virtually every subgroup we have analyzed, including elderly patients and those with renal impairment" [5].

How to Process the Switch Through Centene

Your physician should submit a PA request documenting the clinical rationale for the switch. Include the patient's time in therapeutic range on warfarin (if below 65%), any bleeding events, INR instability records, and relevant comorbidities. Centene pharmacy benefit managers review these requests against internal clinical criteria derived from FDA labeling and major society guidelines. Approval rates for warfarin-to-DOAC switches are generally high when documentation is thorough.

What to Do if Centene Denies Eliquis Coverage

A denial does not have to be the final answer. The appeals process provides a structured path to overturn the decision.

Internal Appeal

File a first-level internal appeal within 60 days of the denial notice (180 days for Medicare plans). Include a letter of medical necessity from the prescribing physician, relevant lab work (renal function, prior INR records if switching from warfarin), and copies of guideline recommendations supporting DOAC use. Centene must respond within 30 days for standard appeals or 72 hours for expedited appeals under CMS guidelines [1].

External Review

If the internal appeal is denied, you have the right to request an independent external review. An external review organization (ERO), unaffiliated with Centene, evaluates the clinical evidence. For Medicare plans, the appeal escalates through the Part D appeals process: first to the Independent Review Entity (IRE), then potentially to an administrative law judge for claims exceeding the minimum threshold ($190 in 2026).

Peer-to-Peer Review

Before or during the appeals process, your physician can request a peer-to-peer call with a Centene medical director. These calls allow direct discussion of the patient's clinical circumstances and often resolve coverage disputes faster than written appeals alone.